The DOI matches its Crossref record.
New drug development in the United States from 1963 to 1999
Abstract
Clinical Pharmacology & Therapeutics (2001) 69, 286–296; doi: 10.1067/mcp.2001.115132
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Self-citationInnovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Self-citationMolecular imaging in drug development
Willmann, J. K., van Bruggen, N., Dinkelborg, L. M., & Gambhir, S. S. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2290 · Cited by 1,171
Drug development for neglected diseases: a deficient market and a public-health policy failure
Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R., & Ford, N. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09096-7 · Cited by 893
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.295 · Cited by 845
Self-citationExploiting drug-disease relationships for computational drug repositioning
Dudley, J. T., Deshpande, T., & Butte, A. J. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr013 · Cited by 524
Key factors in the rising cost of new drug discovery and development
Dickson, M., & Gagnon, J. P. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1382 · Cited by 498
The outsourcing of R&D through acquisitions in the pharmaceutical industry
Higgins, M. J., & Rodriguez, D. (2006) · Journal of Financial Economics · doi:10.1016/j.jfineco.2005.04.004 · Cited by 460
Predicting drug-disease associations by using similarity constrained matrix factorization
Zhang, W., Yue, X., Lin, W., Wu, W., Liu, R., Huang, F., & Liu, F. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2220-4 · Cited by 303
Adipokines – removing road blocks to obesity and diabetes therapy
Blüher, M. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.01.005 · Cited by 273
Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses
Chiang, A. P., & Butte, A. J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.103 · Cited by 268
Zebrafish as a correlative and predictive model for assessing biomaterial nanotoxicity
Fako, V. E., & Furgeson, D. Y. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.008 · Cited by 261
Trends in development and approval times for new therapeutics in the United States
Reichert, J. M. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1178 · Cited by 260
Physiologically-based pharmacokinetic simulation modelling
Grass, G. M., & Sinko, P. J. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00013-3 · Cited by 160
Liquid-based three-dimensional tumor models for cancer research and drug discovery
Ham, S. L., Joshi, R., Thakuri, P. S., & Tavana, H. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216643772 · Cited by 91
Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery
McArthur, R. A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.02.004 · Cited by 42
Beierlein, J. M., McNamee, L. M., Walsh, M. J., Kaitin, K. I., DiMasi, J. A., & Ledley, F. D. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.06.001 · Cited by 24
Self-citation
Metadata
- Authors
- DiMasi, J. A.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2001-05
- Volume
- 69
- Issue
- 5
- Pages
- 286-296
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2031723179
- Cited by
- 251
- References
- 0
- FWCI
- 26.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.